Skip To Main Content
John Hural on Muck Rack

John Hural

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to John Hural’s profile

Articles by John Hural

mRNA-1273 SARS-CoV-2 vaccination in people with HIV: an immune correlates analysis of CD4 + T cell responses in the multicenter CoVPN 3008 observational study

|
By Sharon Khuzwayo, Bo Zhang, Valentin Voillet, Lindsay N. Carpp, James Peng, Jiani Hu, Katharine Schwedhelm, Erica Smit, Craig A Magaret, Zhe Chen, Siyu Heng, Yutong Jin, Peter Elyanu, Asa Tapley, Aaron Hudson, Sinethemba Bhebhe, Haajira Kaldine, Prudence Kgagudi, Tandile Hermanus, Jessica Andriesen, April K. Randhawa, Leigh H. Fisher, Manuel Villaran, Margaret Yacovone, Taraz Samandari, Zvavahera M. Chirenje, Sharlaa Badal-Faesen, William Brumskine, Rodney Dawson, Sinead Delany-Moretlwe, Andreas Henri Diacon, Samantha Fry, Katherine Gill, Mina C. Hosseinipour, Craig Innes, Steve Innes, Dishiki Kalonji, Margaret P Kasaro, Noel Kayange, William Kilembe, Fatima Laher, Joseph Makhema, Vongane Maluleke, Cissy Kityo Mutuluuza, Pamela Mda, Tumelo Moloantoa, Nivashnee Naicker, Vimla Naicker, Annet Nanvubya, Harriet Nuwagaba-Biribonwoha, Walter Otieno, Elsje Louise Potgieter, Disebo Potloane, Yashna Singh, Myron Cohen, James G. Kublin, Lawrence Corey, Glenda Gray, Yunda Huang, Nyaradzo Mgodi, Sufia Dadabhai, Philip Kotze, Nigel J. Garrett, John Hural, Guido Ferrari, David C. Montefiori, Penny Moore, Georgia Tomaras, Nonhlanhla N. Mkhize, Stephen De Rosa, M. Juliana McElrath, Peter Gilbert, Erica Andersen-Nissen, Faatima Laher Omar, Jia Jin Kee, Laura Polakowski, Soritha Coetzer, Mubiana Inambao, Priya Kassim, Ethel Kamuti, Moelo Malahleha, Matsontso Mathebula, Grace Mboya, Kirsten McHarry, Essack Mitha, Sibekezelo Msomi, Zelda Punt, Mohammed Siddique Tayob, Yacoob Vahed, Joel Maena, Linda- Gail Bekker
| Nature Verified
Abstract T cell correlates of COVID-19 risk are poorly defined, particularly in people with HIV (PWH). CoVPN 3008 (NCT05168813) Part A was a prospective 14,002-participant cohort study that administered one or two doses of mRNA-1273 COVID-19 vaccine, depending on baseline SARS-CoV-2 serostatus, in participants (83% PWH) in sub-Saharan Africa. Participants self-monitored for prespecified COVID-19 symptoms, defined by Centers for Disease Control and Prevention symptom criteria.
Open in Who Shared Issue with article?

Prophylactic treatment with broadly neutralizing antibody VRC01 selects for escape mutants after infection in Antibody-Mediated Prevention trials

|
By Carolyn Williamson, Nonhlanhla N. Mkhize, Elena Giorgi, Craig A Magaret, Bronwen E. Lambson, Sinethemba Bhebhe, Haajira Kaldine, Thandeka Moyo-Gwete, Morgane Rolland, Raabya Rossenkhan, Nina Garcia Verified, Chivonne Moodley, Anna Yssel, Yunda Huang, Daniel Reeves, Bryan Mayer, Roger E. Bumgarner, Nicolas Beaume, Dylan Westfall, Michal Juraska, Allan C. deCamp, Hugh Murrell, Hongjun Bai, Wenjie Deng, Alec Pankow, Tanmoy Bhattacharya, Talita York, Nonkululeko Ndabambi, Lennie Chen, Hong Zhao, Ruwayhida Thebus, Paula Cohen, Ben Murrell, Shelly Karuna, John Hural, Nyaradzo Mgodi, Srilatha Edupuganti, Lynn Morris, David C. Montefiori, M. Juliana McElrath, Myron Cohen, Lawrence Corey, Paul T. Edlefsen, Peter Gilbert, Penny Moore, James Mullins, Lyle Curry, Alaine A. Marsden, Asanda Gwashu-Nyangiri
| Nature Verified
Abstract Broadly neutralizing antibodies (bnAbs) show promise in HIV prevention, yet viral escape remains a challenge. In the Antibody-Mediated Prevention (AMP) trials, the CD4 binding site (CD4bs) bnAb VRC01 blocked acquisition by VRC01-sensitive strains. However, its influence on viral evolution post acquisition is not fully understood.
Open in Who Shared Issue with article?

Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infection

|
By James Mullins, Wenjie Deng, Elena Giorgi, Craig A Magaret, Morgane Rolland, Tanmoy Bhattacharya, Dylan Westfall, Anna Yssel, Roger E. Bumgarner, Ben Murrell, Thumbi Ndung’u, Merlin L. Robb, Raabya Rossenkhan, Paul T. Edlefsen, Krista L Dong, Lennie Chen, Asanda Gwashu-Nyangiwe, Hong Zhao, Ruwayhida Thebus, Nonkululeko Ndabambi, Sorachai Nitayaphan, Talita York, David Matten, Hugh Murrell, Alec Pankow, Michal Juraska, James Ludwig, John Hural, Myron Cohen, Lawrence Corey, M. Juliana McElrath, Peter Gilbert, Carolyn Williamson, Bruna Galvao, Fredrick Sawe
| Nature Verified
Abstract Understanding the selective forces acting upon HIV early in infection is crucial to design prevention strategies. By leveraging deep sequencing and the short diagnostic intervals of the FRESH and RV217 cohorts between the last-negative and first-positive RNA tests (median 4 days), we captured a precise and early snapshot of acute HIV infection.
Open in Who Shared Issue with article?

Viral variant but not host factors associate with SARS-CoV-2 viral kinetics

|
By William Hahn, Amy Ward, Shannon Grant, Catherine Yen, April Kaur Randhawa, Xiaohong Li, Shelly Anne Ramirez, John Hural, Pavitra Roychoudhury, Colleen Kelley, Nadine Rouphael, Valeria D. Cantos, Jorge A. Pinto, Pedro Cahn, Joseph Makhema, Lynda Stranix-Chibanda, Marcelo H. Losso, Craig Innes, Lameck Chinula, Javier R. Lama, Roma Chilengi, Maphoshane Nchabeleng, Hong-Van Tieu, Brenda Hoagland, Beatriz Grinsztejn, William Brumskine, Khatija Ahmed, Carole L Wallis, Alexander L. Greninger, Lawrence Corey, Ollivier Hyrien, Leigh H. Fisher, Nicole Espy, Jennifer Hanke, Mmatsie Manentsa, Wadzanai Samaneka, Muchaneta Bhondai-Mhuri, Jorge A. Gallardo-Cartagena, Chishiba Kabengele
| Nature Verified
Abstract It is challenging to assess SARS-CoV-2 viral kinetics amidst viral variant evolution and changes in population-level immunity. However, understanding the relationship between host factors and viral replication deepens our understanding of viral fitness. In CoVPN 5001, we enrolled N = 953 adults diagnosed with acute SARS-CoV-2 from July 2020 to July 2022 across 51 sites. We confirmed SARS-CoV-2 infection by RT-PCR and identified the variant via viral genome sequencing.
Open in Who Shared Issue with article?

Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials

|
By Carolyn Williamson, Chivonne Moodley, Craig A Magaret, Elena Giorgi, Morgane Rolland, Dylan Westfall, Anna Yssel, Wenjie Deng, Nonhlanhla N. Mkhize, Lennie Chen, Hong Zhao, Tanmoy Bhattacharya, Alec Pankow, Ben Murrell, Ruwayhida Thebus, Paula Cohen Verified, Bronwen E. Lambson, Michal Juraska, Hongjun Bai, Allan C. deCamp, Maurine D Miner, James Ludwig, Yunda Huang, Lily Zhang, Daniel Reeves, Bryan Mayer, Shelly Karuna, John Hural, Lynn Morris, David C. Montefiori, Penny Moore, Paul T. Edlefsen, Srilatha Edupuganti, Nyaradzo Mgodi, M. Juliana McElrath, Myron Cohen, Lawrence Corey, Peter Gilbert, James Mullins, Raabya Rossenkhan, Talita York, Asanda Gwashu-Nyangiwe, Nonkululeko Ndabambi, Haajira Kaldine, Sinethemba Bhebhe, Cindy Molitor, Nicolas Beaume, David Matten, Roger E. Bumgarner
| Nature Verified
Abstract In the antibody mediated prevention (AMP) trials, the broadly neutralizing antibody (bNAb) VRC01 demonstrated protective efficacy against susceptible HIV strains. To understand how VRC01 shaped breakthrough infections, deep sequencing was performed on 172 participants (>100,000 gag-Δpol and rev-env-Δnef sequences), at diagnosis and over time, in the placebo and treatment arms of the African (HVTN703/HPTN081; NCT02568215) and Americas/Europe (HVTN704/HPTN085; NCT02716675) cohorts.
Open in Who Shared Issue with article?
Show More